首页> 外文期刊>Scientific reports. >Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route
【24h】

Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route

机译:与皮内途径相比,基于腺病毒的疟疾疫苗的微针介导免疫增强了抗原特异性抗体的免疫力,并降低了抗载体反应

获取原文
           

摘要

Substantial effort has been placed in developing efficacious recombinant attenuated adenovirus-based vaccines. However induction of immunity to the vector is a significant obstacle to its repeated use. Here we demonstrate that skin-based delivery of an adenovirus-based malaria vaccine, HAdV5-PyMSP142, to mice using silicon microneedles induces equivalent or enhanced antibody responses to the encoded antigen, however it results in decreased anti-vector responses, compared to intradermal delivery. Microneedle-mediated vaccine priming and resultant induction of low anti-vector antibody titres permitted repeated use of the same adenovirus vaccine vector. This resulted in significantly increased antigen-specific antibody responses in these mice compared to ID-treated mice. Boosting with a heterologous vaccine; MVA-PyMSP142 also resulted in significantly greater antibody responses in mice primed with HAdV5-PyMSP142 using MN compared to the ID route. The highest protection against blood-stage malaria challenge was observed when a heterologous route of immunization (MN/ID) was used. Therefore, microneedle-mediated immunization has potential to both overcome some of the logistic obstacles surrounding needle-and-syringe-based immunization as well as to facilitate the repeated use of the same adenovirus vaccine thereby potentially reducing manufacturing costs of multiple vaccines. This could have important benefits in the clinical ease of use of adenovirus-based immunization strategies.
机译:人们已经在开发有效的基于重组减毒腺病毒的疫苗上投入了大量精力。然而,对载体的免疫诱导是其重复使用的重要障碍。在这里,我们证明了使用硅微针将基于腺病毒的疟疾疫苗HAdV5-PyMSP1 42 通过基于皮肤的方式传递给小鼠会诱导对编码抗原的等效或增强的抗体反应,但是会导致抗-载体反应,与皮内给药相比。微针介导的疫苗引发和由此产生的低抗载体抗体滴度的诱导允许重复使用相同的腺病毒疫苗载体。与ID治疗的小鼠相比,这导致这些小鼠的抗原特异性抗体应答显着增加。用异源疫苗加强免疫;与ID途径相比,MVA-PyMSP1 42 在使用MN接种HAdV5-PyMSP1 42 的小鼠中也产生了明显更高的抗体应答。当使用异源免疫途径(MN / ID)时,观察到针对血液阶段疟疾攻击的最高保护。因此,微针介导的免疫具有克服围绕基于针和注射器的免疫的一些逻辑障碍以及促进重复使用相同的腺病毒疫苗的潜力,从而潜在地降低了多种疫苗的生产成本。这在基于腺病毒的免疫策略的临床易用性方面可能具有重要的益处。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号